Drug Profile
Mirikizumab - Eli Lilly and Company
Alternative Names: IL-23 antibody - Eli Lilly and Company; IL-23p19 antibody - Eli Lilly and Company; LY 3074828; Miri - Eli Lilly and Company; OMVOH; OmvohLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Phase III Crohn's disease
- Discontinued Plaque psoriasis
Most Recent Events
- 13 Mar 2024 Phase-III clinical trials in Crohn's disease (In children, In adolescents) in Austria, Belgium, Brazil, France, Israel, South Korea, Italy, Netherlands, Norway, Poland, Portugal, Spain, United Kingdom (SC) (NCT05509777)
- 13 Mar 2024 Phase-III clinical trials in Crohn's disease (In children, In adolescents) in United Kingdom, Belgium, Poland, Portugal, Austria, Brazil, France, Israel, Italy, Japan, South Korea, Netherlands, Norway, Spain, USA (IV) (NCT05509777)
- 13 Mar 2024 Eli Lilly and Company initiated a Phase-III clinical trials in Crohn's disease (In children, In adolescents) in USA and Japan (SC) (NCT05509777)